'Metastatic prostate cancer' presentation slideshows

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001. STAMPEDE uses multi-arm multi-stage methodology

961 views • 66 slides

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001. STAMPEDE uses multi-arm multi-stage methodology

970 views • 66 slides

The genetics of heterochromatin in metazoa

The genetics of heterochromatin in metazoa. Hermann Joseph Muller 1946 Nobel Prize in Medicine: "for the discovery of the production of mutations by means of X-ray irradiation". The true meaning of "red eye reduction":. White wild-type White mutant. 12.14. 12.14.

686 views • 54 slides

First line cytotoxic treatment in castration resistant prostate cancer: What have we learned in the last twenty years?

First line cytotoxic treatment in castration resistant prostate cancer: What have we learned in the last twenty years?. Ian F Tannock MD, PhD, DSc Princess Margaret Hospital and University of Toronto. Learning Goals of Presentation. To become familiar with:

647 views • 44 slides

Genetic Causation for Mortality Disparity among Young African-American Men

Genetic Causation for Mortality Disparity among Young African-American Men. Clinical and Genetic Evidence Support a Faster Growth Rate of Prostate Cancer among African American Compared to European American Men. Incidence by Ethnicity per 100,000 Men 2006 (SEER 2009 Data) Black 239.8

457 views • 32 slides

Rationale for Radical Prostatectomy for Noncastrate Oligometastatic Prostate Cancer

Rationale for Radical Prostatectomy for Noncastrate Oligometastatic Prostate Cancer. Karim Touijer, MD, MPH, FACS. Attending Surgeon Memorial Sloan-Kettering Cancer Center Professor of Urology Weill Cornell Medical College, New York. Newly diagnosed synchronous M1 prostate cancer

300 views • 29 slides

484 views • 25 slides

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. Presented By Christopher Sweeney at 2014 ASCO Annual Meeting. A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer.

552 views • 24 slides

Early Diagnosis, Treatment Matter with Prostate Cancer

To be sure, the task force took the PSA off the table with good intentions. Prostate cancer is known to be generally low risk and rather slow growing.

68 views • 2 slides

Figure 1 Therapy-induced mechanisms of resistance in metastatic prostate cancer

Figure 1 Therapy-induced mechanisms of resistance in metastatic prostate cancer. Claessens, F. et al. (2014) Emerging mechanisms of enzalutamide resistance in prostate cancer Nat. Rev. Urol. doi:10.1038/nrurol.2014.243.

222 views • 1 slides

Prostate Cancer Survival Rate

A proper understanding of what prostate cancer survival rate actually means will help you to avoid some misconceptions often made by people. The survival rate of prostate cancer only tells the likelihood of getting a successful treatment for each stage of the prostate cancer.

29 views • 1 slides